NEW YORK, Dec. 22, 2017 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on BCR, GKOS, WAT, and COO which can be accessed for free by signing up to www.wallstequities.com/registration. On Thursday, December 21, 2017, the NASDAQ Composite ended the trading session
Murray Hill, New Jersey headquartered C.R. Bard Inc.'s stock finished Thursday's session 0.35% lower at $331.40 with a total trading volume of 384,688 shares. The Company's shares have advanced 50.87% over the past twelve months and 47.51% since the start of this year. The stock is trading above its 200-day moving average by 7.04%. Additionally, shares of C.R. Bard, which together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide, have a Relative Strength Index (RSI) of 44.48. Get the full research report on BCR for free by clicking below at:
On Thursday, shares in San Clemente, California headquartered Glaukos Corp. recorded a trading volume of 147,940 shares. The stock ended the session 1.52% lower at $26.60. The Company's shares have advanced 4.93% in the last month. The stock is trading below its 50-day moving average by 10.39%. Moreover, shares of Glaukos, which focuses on the development and commercialization of products and procedures designed to treat glaucoma, have an RSI of 45.41. Get access to our top-rated research, including the free report on GKOS at:
Milford, Massachusetts-based Waters Corp.'s shares closed the day 0.79% lower at $194.52. The stock recorded a trading volume of 294,017 shares. The Company's shares have gained 43.41% over the last twelve months and 44.74% since the start of the year. The stock is trading above its 50-day and 200-day moving averages by 0.12% and 7.99%, respectively. Additionally, shares of Waters, which operates as an analytical instrument manufacturer in the US and internationally, have an RSI of 47.65.
On December 04th, 2017, research firm Morgan Stanley upgraded the Company's stock rating from 'Underweight' to 'Equal-Weight'. Click here to subscribe for a free membership which welcomes you with our report on WAT at:
Shares in Pleasanton, California headquartered The Cooper Cos. Inc. finished 1.26% lower at $221.77. The stock recorded a trading volume of 343,253 shares. The Company's shares have advanced 27.00% over the last twelve months and 26.78% on an YTD basis. The stock is trading below its 50-day moving average by 5.54%. Furthermore, shares of Cooper, which operates as a medical device company worldwide, have an RSI of 37.21.
On December 08th, 2017, research firm Stifel reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $275 a share to $265 a share. Join our big investor community at Wall St. Equities today and start so with your free report on COO at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.org Phone number: +21-32-044-483 Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/stock-review-for-medical-supplies-investors----cr-bard-glaukos-waters-and-cooper-300574908.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Abortion pills are used in the first trimester to terminate pregnancy. Women should be aware of ...
Tea tree oil is an essential oil derived from the leaves of the Melaleuca alternifolia plant and ...
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...View All